Abstract
Background Despite advances in managing traditional risk factors, coronary artery disease (CAD) remains the leading cause of mortality. Circulating hematopoietic cells influence risk for CAD, but the role of a key regulating organ, spleen, is unknown. The understudied spleen is a 3-dimensional structure of the hematopoietic system optimally suited for unbiased radiologic investigations toward novel mechanistic insights.
Methods Deep learning-based image segmentation and radiomics techniques were utilized to extract splenic radiomic features from abdominal MRIs of 42,059 UK Biobank participants. Regression analysis was used to identify splenic radiomics features associated with CAD. Genome-wide association analyses were applied to identify loci associated with these radiomics features. Overlap between loci associated with CAD and the splenic radiomics features was explored to understand the underlying genetic mechanisms of the role of the spleen in CAD.
Results We extracted 107 splenic radiomics features from abdominal MRIs, and of these, 10 features were associated with CAD. Genome-wide association analysis of CAD-associated features identified 219 loci, including 35 previously reported CAD loci, 7 of which were not associated with conventional CAD risk factors. Notably, variants at 9p21 were associated with splenic features such as run length non-uniformity.
Conclusions Our study, combining deep learning with genomics, presents a new framework to uncover the splenic axis of CAD. Notably, our study provides evidence for the underlying genetic connection between the spleen as a candidate causal tissue-type and CAD with insight into the mechanisms of 9p21, whose mechanism is still elusive despite its initial discovery in 2007. More broadly, our study provides a unique application of deep learning radiomics to non-invasively find associations between imaging, genetics, and clinical outcomes.
Competing Interest Statement
VR has Common stock in NVIDIA, Alphabet, Apple, and Meta. RB has been a advisor to Casana Care, Inc., unrelated to the current work. PL is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron. PL is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Otalec Therapeutics, Medimmune, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Therapeutics, and XBiotech, Inc. PL's laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk, and Genentech. PL is on the Board of Directors of XBiotech, Inc. PL has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. PL's interests are reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. PL receives funding support from the National Heart, Lung, and Blood Institute (IR01HL134892, 1R01HL163099-01, RO1AG063839, R01HL151627, R01HL157073, R01H166538), the RRM Charitable Fund, and the Simard Fund. PE is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular disease. PE has consulted for Bayer AG, Novartis, MyoKardia, and Quest Diagnostics. AP is a general partner at Google Ventures. PN reports grant support from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, spousal employment and equity at Vertex, consulting income from Apple, AstraZeneca, Novartis, Genentech/Roche, Blackstone Life Sciences, Foresite Labs, and TenSixteen Bio, and is a scientific advisor board member and shareholder of TenSixteen Bio and geneXwell, all unrelated to this work. MK, BT, AA, AS, SF, CR, MM, WH, ZY have no disclosures to disclose.
Funding Statement
MK received support from the Harvard MIT Health Sciences and Technology program and Harvard Medical School Office of Scholarly Engagement. VR received support from American Heart Association Career Development Award 935176 NHLBI 1K01Hl168231. RB is supported by Harvard Catalyst K12 Award. PE is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular disease, funding from the Fondation Leducq (14CVD01), by grants from the National Institutes of Health (1RO1HL092577, K24HL105780) and by a grant from the American Heart Association (18SFRN34110082). PL receives funding support from the National Heart, Lung, and Blood Institute (1R01HL134892, 1R01HL163099-01, R01AG063839, R01HL151627, R01HL157073, R01HL166538), the RRM Charitable Fund, and the Simard Fund. ZY is supported by 1K99HG012956-01. P.N. is supported by grants from the NHLBI (R01HL142711, R01HL127564, R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125782), Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Paul and Phyllis Fireman Endowed Chair in Vascular Medicine).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank individual-level data are available for request by application (https://www.ukbiobank.ac.uk). All code used for the described analysis will be uploaded to GitHub once the manuscript is accepted for publication. All extracted splenic radiomics features will be submitted to UK Biobank once the manuscript is accepted for publication.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract revised to highlight 9p21.
Data Availability
UK Biobank individual-level data are available for request by application (https://www.ukbiobank.ac.uk). All code used for the described analysis will be uploaded to GitHub once the manuscript is accepted for publication. All extracted splenic radiomics features will be submitted to UK Biobank once the manuscript is accepted for publication.
